ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "complement"

  • Abstract Number: 0298 • ACR Convergence 2024

    RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults

    Miwa Haranaka1, Akinori Yamada2, Saki Takahashi2, Keisuke Gotanda2, Sonoko Nakano-Kanatani2, Nana Uemura2, Kensuke Ohnishi2, Masanobu Nishidate2, Ichio Ohnami2 and Megumi Kai3, 1Souseikai Hakata Clinic, Fukuoka, Japan, 2Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, 3Oita University, Oita, Japan

    Background/Purpose: Complement C1s is one of the major components of the classical complement pathway (CP), and the abnormal activation of CP is implicated in several…
  • Abstract Number: 2478 • ACR Convergence 2024

    Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial

    Christian Pagnoux1, Antoine Neel2, Sarah Bray3, Rachel E. Gurlin4, Darcy Trimpe5, David Jayne6 and Peter Merkel7, and ADVOCATE Study Group, 1Mount Sinai Hospital, Toronto, ON, Canada, 2Department of Internal Medicine, CHU Nantes, Nantes, France, 3Amgen Ltd, Cambridge, United Kingdom, 4Amgen Inc., Mountain View, CA, 5Amgen Inc., Thousand Oaks, CA, 6University of Cambridge, Cambridge, United Kingdom, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are subtypes of ANCA-associated vasculitis that frequently involve the kidneys. However, a subset of patients with…
  • Abstract Number: 0461 • ACR Convergence 2024

    Complete Description of the Three Pathways of the Complement System in a Series of 430 Patients with Rheumatoid Arthritis

    ivan Ferraz-Amaro1, Maria Garcia-Gonzalez2, Fuensanta Gomez-Bernal3, Juan Carlos Quevedo-Abeledo4 and Miguel Angel Gonzalez-Gay5, 1Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 2Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, 3Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 4Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 5University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain

    Background/Purpose: The complement (C) system has been implicated in the etiopathogenesis of rheumatoid arthritis (RA). We aimed to examine the correlation between an in-depth evaluation…
  • Abstract Number: 2480 • ACR Convergence 2024

    Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial

    Robert Spiera1, Robert Lebovics2, Sarah Bray3, Rachel E. Gurlin4, David Jayne5 and Peter Merkel6, and ADVOCATE Study Group, 1Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 2Hackensack Meridian University Health System, Hackensack, NJ, 3Amgen Ltd, Cambridge, United Kingdom, 4Amgen Inc., Mountain View, CA, 5University of Cambridge, Cambridge, United Kingdom, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: In the phase 3 ADVOCATE trial, 45.2% and 42.1% of patients in the avacopan and prednisone taper groups, respectively, had active ear, nose, or…
  • Abstract Number: 0471 • ACR Convergence 2024

    Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients with Rheumatoid Arthritis

    Jose Viotti-Serra1, Maria Garcia-Gonzalez2, Fuensanta Gomez-Bernal1, Juan Carlos Quevedo-Abeledo3, Miguel Angel Gonzalez-Gay4 and ivan Ferraz-Amaro5, 1Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 2Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

    Background/Purpose: The complement (C) system has been associated with the etiopathogenesis of rheumatoid arthritis (RA). Insulin resistance (IR) and metabolic syndrome are prevalent among RA…
  • Abstract Number: 2483 • ACR Convergence 2024

    Efficacy and Safety of Avacopan over 12 Months in Japanese Patients with MPA/GPA: A Single-center Study

    Yusuke Ushio1, Hiromi Shimada2, taichi miyagi3, Koichi Sugihara4, Mao Mizusaki5, Rina Mino5, Hayamasa yamaguchi5, Naoto Manabe5, Shusaku Nakashima2 and Hiroaki Dobashi2, 1Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, 2Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 3Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, kidagun, Japan, 4Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan, 5Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan

    Background/Purpose: Avacopan, an oral C5a receptor inhibitor, was demonstrated to be an alternative to glucocorticoids (GC) in the treatment of microscopic polyangiitis (MPA)/granulomatosis with polyangiitis…
  • Abstract Number: 0497 • ACR Convergence 2024

    Relationship Between the Complement System and Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis

    Adrián Quevedo-Rodríguez1, Marta Hernández-Díaz2, Dara Rodríguez-González22, Fuensanta Gomez-Bernal3, Juan Carlos Quevedo-Abeledo4, Agustín F González-Rivero2, Elena González López5, gonzalo Ocejo-Viñals5, Miguel Angel Gonzalez-Gay6 and ivan Ferraz-Amaro7, 1Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 2Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, 3Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 4Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 5Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, 6University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 7Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

    Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Carotid subclinical atherosclerosis is independently associated with incident…
  • Abstract Number: 2488 • ACR Convergence 2024

    Patient Characteristics and Treatment Patterns Before and After Initiation of Avacopan in the United States: An Early View Based on a Claims Database Analysis

    Sushmitha Inguva1, Pallavi Rane1, Darcy Trimpe1, Sam Oh1, Jasjit Multani2, Hsiu-Ching Chang2, Marie Yasuda2, Chi-Chang Chen2, Duvuru Geetha3, Peter Merkel4 and Zachary Wallace5, 1Amgen Inc., Thousand Oaks, CA, 2IQVIA, Wayne, PA, 3Johns Hopkins University, Baltimore, MD, 4University of Pennsylvania, Philadelphia, PA, 5Massachusetts General Hospital, Newton, MA

    Background/Purpose: The United States (US) Food and Drug Administration approved avacopan to treat adults with severe active granulomatosis with polyangiitis or microscopic polyangiitis in October…
  • Abstract Number: 0608 • ACR Convergence 2024

    Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort

    Andrew Concoff1, Touba Warsi2, Sepehr Taghavi2, Sudha Kumar2, Abigail Patalinghug2, Christine Schleif2, Brittany Partain3, Joseph Ahearn4, Chau-Ching Liu5, Nicole Wilson5, Susan Manzi5 and Tyler O'Malley6, 1Exagen, Inc., Los Angeles, CA, 2Exagen, Carlsbad, CA, 3Exagen, Boston, MA, 4Allegheny Health Network, Wexford, PA, 5Allegheny Health Network, Pittsburgh, PA, 6Exagen, Vista, CA

    Background/Purpose: Cell bound complement activation products (CB-CAPs) including erythrocyte-bound C4d (EC4d) and B-lymphocyte C4d (BC4d) demonstrate increased diagnostic accuracy compared to conventional SLE markers (anti-dsDNA,…
  • Abstract Number: 2534 • ACR Convergence 2024

    Deciphering Complement-dependent Macrophage Phenotypes in Human Rheumatoid Arthritis Using Combined Computational-experimental Single-cell Omics

    Juan Vargas1, Ian Mantel2, Jun Inamo3, Nirmal Banda1, Anna Helena Jonsson3, Kevin Wei4, Deepak Rao5, Susan Goodman6, Kevin Deane7, Jennifer Seifert8, Jennifer Anolik9, Michael Brenner10, Soumya Raychaudhuri11, Trent Woodruff12, the Accelerating Medicines Partnership (AMP) RA/SLE Network13, Michael Holers14, Laura Donlin15 and Fan Zhang16, 1The University of Colorado, Aurora, CO, 2WEILL CORNELL MEDICINE, New York, NY, 3University of Colorado School of Medicine, Aurora, CO, 4Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6Hospital for Special Surgery, New York 10025, NY, 7University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 8University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, 9University of Rochester Medical Center, Rochester, NY, 10Brigham Women's Hospital, Boston, MA, 11Brigham and Women's Hospital, Boston, MA, 12University of Queensland, Brisbane, Australia, 13AMP RA/SLE consortium, Aurora, CO, 14Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 15Hospital for Special Surgery, New York, NY, 16University of Colorado, Aurora, CO

    Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune disease pathogenesis. In patients…
  • Abstract Number: 0617 • ACR Convergence 2024

    Hereditary C1q Deficiency Is Associated with Type 1 Interferon-pathway Activation and a High Risk of Central Nervous System Inflammation

    Clément triaille1, Neha Mohan Rao2, Gillian Rice3, Luis Seabra4, Sutherland Fraser5, Vincent Bondet6, Darragh duffy6, Andrew Gennery7, Benjamin Fournier8, Brigitte Bader-Meunier9, Christopher Troedson10, Gavin CLeary11, Helena Buso12, Jacqueline Dalby-Payne13, Ranade Prajakta14, Katrien Jansen15, Lien De Somer16, Marie-Louise Fremond17, Pimple Pallavi14, Melanie Wong18, Russel Dale10, Carine Wouters16, PIERRE QUARTIER19, Raju Khubchandani20 and Yanick Crow5, 1Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Brussels, Belgium, 2NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, 3Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, 4Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France, Paris, France, 5MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom, Edinburgh, United Kingdom, 6Translational Immunology Unit, Institut Pasteur, Université Paris-Cité, Paris, France, Paris, France, 7: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, Newcastle, United Kingdom, 8Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, France, 9Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, 10T. Y. Nelson Department of Neurology and Neurosurgery, Children's Hospital at Westmead, Westmead, New South Wales, and University of Sydney, Australia, Sydney, Australia, 11: Paediatric Rheumatology, Alder Hey Children's Hospital, Liverpool, United Kingdom, Liverpool, United Kingdom, 12Department of Medicine - DIMED, University of Padova, Padova, Italy, Padova, Italy, 13Specialty of Child and Adolescent Health, Faculty of Medicine, The University of Sydney, Australia, Sydney, Australia, 14NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, India, 15Division of Pediatric Neurology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, 16Division of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, 17Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, United Kingdom, 18Department of Allergy and Immunology, Children's Hospital at Westmead, Westmead, Australia, Westmead, Australia, 19Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France, 20SRCC Childrens Hospital, Mumbai, India

    Background/Purpose: To report on the largest cohort of C1Q deficient (C1QDef ) patients; to investigate the activation of Type 1 interferon pathway in the blood…
  • Abstract Number: 0629 • ACR Convergence 2024

    Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus

    Anca Askanase1, Edward Vital2, Oliver Meier3, Armando Turchetta4, Huiyan (Ashley) Mao4, Justine Maller5, Jorge A. Ross Terres6 and Maria Dall'Era7, 1Columbia University Medical Center, New York, NY, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland, 4Hoffmann-La Roche Ltd, Mississauga, Canada, 5Genentech, Inc,, San Francisco, CA, 6Genentech, Inc,, San Francisco, 7UCSF, Corte Madera, CA

    Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…
  • Abstract Number: 0669 • ACR Convergence 2024

    Efficacy of Belimumab in Systemic Lupus Erythematosus: A Single-Centre Retrospective Study

    buddhika Jayaratna1, Pasan Serasinghe2, Louise Nel3, Sahil Jain3, Shrish Sangle2, Begona Lopez1, Giovanni Sanna2, Michelle Fernando1 and David DCruz4, 1Guys & St Thomas NHS Foundation Trust, London, United Kingdom, 2Guys & St Thomas NHS Foundation Trust, London, England, United Kingdom, 3Guys and St Thomas' Hospital, London, United Kingdom, 4The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multi-system autoimmune rheumatic disorder. Despite therapeutic advances, managing SLE remains challenging due to its complex pathogenesis and…
  • Abstract Number: 1378 • ACR Convergence 2024

    Tocilizumab Effect on the Three Pathways of the Complement System in Patients with Rheumatoid Arthritis

    Marta Hernández-Díaz1, Iván Ferraz-Amaro2, Sergio Santos-Concepción3, Javier Castro3, Vanesa Hernandez4, Beatriz Tejera Segura5, Cristina Luna6, Esmeralda Delgado-Frías2 and Federico Diaz-González2, 1Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, 2Hospital Universitario de Canarias, La Laguna, Spain, 3Universidad de La Laguna, La Laguna, Spain, 4Rheumatology department. Hospital Universitario de Canarias, La Laguna, Spain, 5Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, 6Hospital Universitario Nuestra Señora de La Candelaria, Santa Cruz, Spain

    Background/Purpose: Tocilizumab (TCZ) is used in diseases characterized by markedly elevated inflammatory markers and elevated pro-inflammatory cytokines like rheumatoid arthritis (RA), juvenile idiopathic arthritis and…
  • Abstract Number: 1490 • ACR Convergence 2024

    Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests

    Vasileios Kyttaris1, Andrew Concoff2, Touba Warsi3, Sepehr Taghavi3, Sudha Kumar3, Stanley Park3, Abigail Patalinghug3, Christine Schleif3, Brittany Partain4, Joseph Ahearn5, Nicole Wilson6, Chau-Ching Liu6, Susan Manzi6 and Tyler O'Malley7, 1BIDMC, Boston, MA, 2Exagen, Inc., Los Angeles, CA, 3Exagen, Carlsbad, CA, 4Exagen, Boston, MA, 5Allegheny Health Network, Wexford, PA, 6Allegheny Health Network, Pittsburgh, PA, 7Exagen, Vista, CA

    Background/Purpose: Conventional SLE diagnostic markers lack sensitivity and are biased towards severe disease, resulting in a subset of clinically ambiguous ANA-positive but specific autoantibody-negative patients.…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology